Lighthouse Pharmaceuticals receives a $49.2 million grant from the National Institute on Aging, aimed at advancing a Phase 2 ...

Alpha1H shows benefit in non-muscle invasive bladder cancer, shrinking tumors and boosting the immune system with manageable ...

UCLA’s cancer research has been deeply impactful, with millions of people receiving drugs and therapies developed in Bruin ...

TERN-701 is an investigational next-generation oral, allosteric BCR-ABL inhibitor specifically targeting the ABL myristoyl pocket that is being evaluated for the treatment of CML.

A new study led by researchers at the Icahn School of Medicine at Mount Sinai has found that adding the targeted therapy ...

The Business Research Company's Investigational New Drug CDMO Global Market Report 2025 – Market Size, Trends, And Global Forecast 2025-2034 Get 30% Off All Global Market Reports With Code ONLINE30 – ...

Correa and Bergman are co-chairs of the congressional Psychedelics Advancing Therapies (PATH) Caucus. Mercer is a Marine Corps veteran and the executive director of Healing Breakthrough.

Patients with chronic hepatitis B virus (HBV) infection in the immune-tolerant phase may still experience hepatic inflammation and disease progression, and could benefit from early antiviral treatment ...

Following FDA IND clearance for neuropathic pain, the Company is preparing to initiate its U.S. Phase 2a trial in Q4 2025 MIAMI, FL / ACCESS Newswire / August 19, 2025 / MIRA Pharmaceuticals, Inc.

Study met primary endpoint demonstrating barzolvolimab’s ability to potently deplete mast cells in the gastrointestinal tractProfound mast cell depletion did not result in improved clinical outcomes p ...

The American Diabetes Association Scientific Sessions, held in June, featured cutting-edge science, from new agents to treat ...